Healing effect of ketanserin on chronic leg ulcers in patients with diabetes
- PMID: 16503887
- DOI: 10.1111/j.1468-3083.2006.01422.x
Healing effect of ketanserin on chronic leg ulcers in patients with diabetes
Abstract
Background: The treatment of chronic leg ulcers remains a stubborn problem in many patients. Topical 2% ketanserin ointment, a 5HT2-serotoninergic blocking agent, has been reported to improve healing of decubitus, venous, diabetic and ischaemic ulcers.
Method: The present double-blind intra-individual comparative study was performed in 12 women with diabetes presenting with at least two similar leg ulcers. In each subject, the two lesions were randomly assigned to be treated for 8 weeks by 2% ketanserin ointment or its unmedicated vehicle.
Objective: assessments of the dynamics of wound healing were performed using computerized morphometry. Evaluations were performed at 2-week intervals for 8 weeks.
Results: A significant decrease in relative wound area was observed on the ketanserin-treated ulcers compared with the placebo group.
Conclusion: Topical ketanserin is a valuable therapy for difficult-to-treat leg ulcers.
Similar articles
-
Randomized single-blind trial of topical ketanserin for healing acceleration of diabetic foot ulcers.Arch Med Res. 1997 Spring;28(1):95-9. Arch Med Res. 1997. PMID: 9078595 Clinical Trial.
-
The effect of short-contact topical tretinoin therapy for foot ulcers in patients with diabetes.Arch Dermatol. 2005 Nov;141(11):1373-7. doi: 10.1001/archderm.141.11.1373. Arch Dermatol. 2005. PMID: 16301384 Clinical Trial.
-
Use of topical ketanserin for the treatment of ulcers in leprosy patients.Indian J Lepr. 2001 Apr-Jun;73(2):103-10. Indian J Lepr. 2001. PMID: 11579646 Clinical Trial.
-
Leg ulcers: uncommon presentations.Clin Dermatol. 2005 Nov-Dec;23(6):601-11. doi: 10.1016/j.clindermatol.2005.01.018. Clin Dermatol. 2005. PMID: 16325069 Review.
-
Combining bioengineered human dermal replacement and multilayered compression dressings to manage ulcers in a person with diabetes mellitus: a case study.Ostomy Wound Manage. 2006 May;52(5):60-4. Ostomy Wound Manage. 2006. PMID: 16687770 Review.
Cited by
-
The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-à-go-go-related gene (hERG) potassium channels.Br J Pharmacol. 2008 Oct;155(3):365-73. doi: 10.1038/bjp.2008.261. Epub 2008 Jun 23. Br J Pharmacol. 2008. PMID: 18574455 Free PMC article.
-
Nanoparticles and nanofibers for topical drug delivery.J Control Release. 2016 Oct 28;240:77-92. doi: 10.1016/j.jconrel.2015.10.049. Epub 2015 Oct 28. J Control Release. 2016. PMID: 26518723 Free PMC article. Review.
-
Dressings and topical agents for arterial leg ulcers.Cochrane Database Syst Rev. 2020 Jan 20;1(1):CD001836. doi: 10.1002/14651858.CD001836.pub4. Cochrane Database Syst Rev. 2020. PMID: 31978262 Free PMC article.
-
Pirfenidone Accelerates Wound Healing in Chronic Diabetic Foot Ulcers: A Randomized, Double-Blind Controlled Trial.J Diabetes Res. 2017;2017:3159798. doi: 10.1155/2017/3159798. Epub 2017 Dec 31. J Diabetes Res. 2017. PMID: 29675430 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical